IGF1

Research in the Special Issue of Journal of Pharmaceutical Analysis Uncovers Previously Unexplored Cellular Mechanisms

Retrieved on: 
星期二, 十月 17, 2023
Male, ICH, Myocardial infarction, IGF1, Stroke, Brain, Intracerebral hemorrhage, UPK3B (gene), JPA, Reactive oxygen species, Toxicity, ECM, Patient, Spatial analysis, PLX3397, Journal, Microglia, Mouse, Extracellular matrix, Dick's Picks Volume 13, Transcriptome, Astrocyte, Prognosis, Inflammation, Research, Medical imaging, Pharmaceutical industry, C3

This comprehensive understanding paves the way for them to uncover some intricate and previously unknown disease mechanisms.

Key Points: 
  • This comprehensive understanding paves the way for them to uncover some intricate and previously unknown disease mechanisms.
  • Three articles in the most recent special issue of the Journal of Pharmaceutical Analysis (JPA) discuss how single-cell and spatially resolved omics help unravel intercellular dynamics, aiding the development of novel therapeutic modalities.
  • The article was available online in February 2023 and published in Volume 13, Issue 8 of JPA in August 2023 .
  • Together, these articles enlighten us with a deeper understanding of cellular mechanisms at the single-cell and spatial levels, offering hope for improved treatment strategies in the future.

Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO

Retrieved on: 
星期五, 五月 5, 2023
ENDO, Abstract, Beagle, Hypoparathyroidism, Bicyclic molecule, Acromegaly, Congress, European, CEST, European Society of Endocrinology, Patient, ECE, Therapy, Biology, IGF1, Pharmaceutical industry, Communications satellite, Vaccine

LYON, France and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 25th European Congress of Endocrinology (ECE), which is being held May 13-16 in Istanbul, Turkey, and at the 2023 Endocrine Society Meeting (ENDO), which is being held June 15-18 in Chicago, Illinois.

Key Points: 
  • LYON, France and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 25th European Congress of Endocrinology (ECE), which is being held May 13-16 in Istanbul, Turkey, and at the 2023 Endocrine Society Meeting (ENDO), which is being held June 15-18 in Chicago, Illinois.
  • These presentations cover both of Amolyt’s development programs, eneboparatide entering Phase 3 for hypoparathyroidism and AZP-3813 entering Phase 1 for acromegaly.
  • Details of the presentations are as follows:
    25th European Congress of Endocrinology (ECE) – May 13-16, Istanbul, Turkey
    Title: Eneboparatide, a Novel PTH-1 Receptor Agonist, Has No Impact on Bone Parameters Following Chronic Treatment of Non-Human Primates
    Title: Eneboparatide, a Novel PTH-1 Receptor Agonist, Induces Rapid Reduction and Normalization of Urinary Calcium in Chronic Hypoparathyroid Patients
    Poster Display: 9:40 a.m. CEST on Sunday, May 14 – 3:30 p.m. CEST on Tuesday, May 16
    Title: Treatment of Chronic Hypoparathyroidism by Eneboparatide, a Novel PTH Receptor-1 Agonist: Results from a Phase 2a Study
    Poster Display: 9:40 a.m. CEST on Sunday, May 14 – 3:30 p.m. CEST on Tuesday, May 16
    Title: AZP-3813, a Bicyclic, 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor, Effectively Suppresses IGF1 in Beagle Dogs
    Poster Display: 9:40 a.m. CEST on Sunday, May 14 – 3:30 p.m. CEST on Tuesday, May 16
    2023 Endocrine Society Meeting (ENDO) – June 15-18, Chicago, Illinois
    Title: Repeated Treatment with AZP-3813, a Bicyclic, 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor, Induces Enhanced Suppression of IGF1 in Beagle Dogs
    Title: Treatment of Chronic Hypoparathyroidism with Eneboparatide (AZP-3601), a Novel PTH 1 Receptor Agonist: Results from a Phase 2 Trial
    Session: Bone 2 - PTH-Relevant Biology, Pathophysiology, and Therapeutics
    Title: AZP-3601, a Novel PTH 1 Receptor Agonist, Induces Rapid Reduction and Normalization of Urinary Calcium in Chronic Hypoparathyroid Patients